Immuneering Corporation

NasdaqGM IMRX

Immuneering Corporation Share Price on January 14, 2025: USD 1.95

Immuneering Corporation Share Price is USD 1.95 on January 14, 2025, a -66.15% change year over year. Share price reflects current trading price of a company's stock; influenced by market dynamics and company performance.

Immuneering Corporation 52-week high Share Price is USD 6.76 on February 20, 2024, which is 246.67% above the current Share Price.
Immuneering Corporation 52-week low Share Price is USD 1.03 on August 16, 2024, which is -47.18% below the current Share Price.
Immuneering Corporation average Share Price for the last 52 weeks is USD 2.50.

Key data

Date	Share Price	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)

NasdaqGM: IMRX

Immuneering Corporation

CEO	Dr. Benjamin J. Zeskind M.B.A., Ph.D.
IPO Date	July 30, 2021
Location	United States
Headquarters	245 Main Street
Employees	66
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.

Key trends

Past 5 years